JPWO2021043951A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021043951A5 JPWO2021043951A5 JP2022514767A JP2022514767A JPWO2021043951A5 JP WO2021043951 A5 JPWO2021043951 A5 JP WO2021043951A5 JP 2022514767 A JP2022514767 A JP 2022514767A JP 2022514767 A JP2022514767 A JP 2022514767A JP WO2021043951 A5 JPWO2021043951 A5 JP WO2021043951A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- substituted
- alkylene
- cancer
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19382765.6 | 2019-09-05 | ||
EP19382765 | 2019-09-05 | ||
PCT/EP2020/074695 WO2021043951A1 (en) | 2019-09-05 | 2020-09-04 | Drug antibody conjugates |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022548530A JP2022548530A (ja) | 2022-11-21 |
JPWO2021043951A5 true JPWO2021043951A5 (es) | 2023-09-11 |
Family
ID=67902467
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022514767A Pending JP2022548530A (ja) | 2019-09-05 | 2020-09-04 | 薬物抗体コンジュゲート |
Country Status (6)
Country | Link |
---|---|
US (1) | US20230218774A1 (es) |
EP (1) | EP4025253B1 (es) |
JP (1) | JP2022548530A (es) |
CN (1) | CN114615999B (es) |
TW (1) | TW202122116A (es) |
WO (1) | WO2021043951A1 (es) |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
JPH08500017A (ja) | 1992-08-17 | 1996-01-09 | ジェネンテク,インコーポレイテッド | 二特異的免疫アドヘジン |
ATE279947T1 (de) | 1996-03-18 | 2004-11-15 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
ES2544527T3 (es) | 2002-07-31 | 2015-09-01 | Seattle Genetics, Inc. | Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa |
EP1817059A2 (en) | 2004-12-01 | 2007-08-15 | Genentech, Inc. | Conjugates of 1,8-bis-naphthalimides with an antibody |
PL1928503T3 (pl) | 2005-08-24 | 2012-12-31 | Immunogen Inc | Sposób wytwarzania koniugatów majtazynoid-przeciwciało |
WO2013016120A1 (en) * | 2011-07-22 | 2013-01-31 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Pederin and psymberin agents |
WO2018167270A1 (en) * | 2017-03-17 | 2018-09-20 | Pharma Mar, S.A. | Anticancer compounds |
-
2020
- 2020-09-04 TW TW109130445A patent/TW202122116A/zh unknown
- 2020-09-04 CN CN202080062337.9A patent/CN114615999B/zh active Active
- 2020-09-04 US US17/640,689 patent/US20230218774A1/en active Pending
- 2020-09-04 EP EP20764406.3A patent/EP4025253B1/en active Active
- 2020-09-04 WO PCT/EP2020/074695 patent/WO2021043951A1/en active Search and Examination
- 2020-09-04 JP JP2022514767A patent/JP2022548530A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3125713C (en) | Antibody-pyrrolobenzodiazepine derivative conjugate | |
CA2928794C (en) | Anti-her2 antibody-drug conjugate | |
AU2012338436B2 (en) | Cytotoxic peptides and antibody drug conjugates thereof | |
JP2024508081A (ja) | 生物活性物質コンジュゲート、その調製方法及びその使用 | |
RU2684468C2 (ru) | Новые конъюгаты антител и их применения | |
HRP20230275T1 (hr) | Antitijelo-lijek konjugati koji sadrže derivate ekteinascidina | |
AU2016232839B2 (en) | CD48 antibodies and conjugates thereof | |
RU2015156499A (ru) | Конъюгаты антитела с лекарственным средством | |
CA3090251A1 (en) | Glypican 3 antibodies and conjugates thereof | |
TW202000239A (zh) | 與抗cd19抗體藥物結合物相關之組合物及方法 | |
EP4161582A2 (en) | Antibody-drug conjugates containing an anti-mesothelin antibody and uses thereof | |
CA3173118A1 (en) | Neodegrader conjugates | |
EP4349372A1 (en) | Antibody drug conjugate, and preparation method therefor and use thereof | |
JPWO2020252294A5 (es) | ||
JP2022547434A (ja) | 標的化デンドリマー複合体 | |
JP2023515845A (ja) | 抗-cd56抗体-薬物複合体およびその治療での使用 | |
JP2019507126A5 (es) | ||
JPWO2020084115A5 (es) | ||
JPWO2021043951A5 (es) | ||
CN117159739A (zh) | 抗体偶联药物、其制备方法及应用 | |
JPWO2020166592A1 (ja) | ヘミアスタリン誘導体とその抗体薬物複合体 | |
JPWO2021214126A5 (es) | ||
US20220265821A1 (en) | Composition and methods of targeting the pre-b cell receptor for the treatment of leukemias and lymphomas | |
CA3204418A1 (en) | Linker-payloads and conjugates thereof | |
KR101597105B1 (ko) | 항체-링커-약물 결합체, 그의 제조방법 및 그를 포함하는 항암제 조성물 |